Mengge Zhou

Dr. Mengge Zhou


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 February 2022 in Mayo Clinic Proceedings
Verified
Journal Article
Closed access
MZMengge Zhou
Mengge Zhou
JZJie Zhang
Jie Zhang
JLJing Liu
Jing Liu
SSSidney C. Smith
Sidney C. Smith
CMChangsheng Ma
Changsheng Ma
DZDong Zhao
Dong Zhao

21 June 2023 in International Journal of Public Health
Verified
Journal Article
Open access
YMYuanqi Mi
Yuanqi Mi
MZMengge Zhou
Mengge Zhou
YZYuhong Zeng
Yuhong Zeng
PWPeicheng Wang
Peicheng Wang
LGLiangmin Gao
Liangmin Gao
FCFeng Cheng
Feng Cheng
Objectives: To determine factors associated with late and delayed antiretroviral therapy (ART) initiation in China and provide evidence for HIV prevention.Methods: Logistics regression model was used to determine factors associated with three outcomes: late (CD4 cell count <200 cells/µL or clinical AIDS diagnosis prior to ART initiation), delayed (more than 1 month between HIV diagnosis date and ART initiation) and either late or delayed ART initiation.Results: Multivariable analysis revealed that male, heterosexual, HIV diagnosis before 2014, HBV/HCV seropositive, and tuberculosis were associated with increased odds of all three outcomes. Conversely, married or cohabiting patients were less likely to have delayed ART initiation and either late or delayed ART initiation, while people who inject drugs were more likely to have these two outcomes. Additionally, older age was associated with an increased risk of having either late or delayed ART initiation, but a decreased risk of delayed ART initiation.Conclusion: The proportion of late and delayed ART initiation decreased significantly after the release of the 2016 guidelines in China. To further improve late diagnosis and early treatment, precise interventions for key populations are required.

21 June 2022 in Frontiers in Public Health
Verified
Journal Article
Open access
YMYuanqi Mi
Yuanqi Mi
YZYuhong Zeng
Yuhong Zeng
PWPeicheng Wang
Peicheng Wang
MZMengge Zhou
Mengge Zhou
FCFeng Cheng
Feng Cheng
Objective: Men who have sex with men in China meet the definition of the population at “substantial risk” of contracting human immunodeficiency virus (HIV) according to the World Health Organization; therefore, initiating pre-exposure prophylaxis (PrEP) is recommended for this population. Lack of convincing evidence on cost-effectiveness has resulted in the lack of large-scale PrEP implementation at a national level. The objective of this review is to assess the cost-effectiveness of pre-exposure prophylaxis implementation among men who have sex with men in China.Methods: The following databases were used to search studies of pre-exposure prophylaxis in China in both English and Chinese: PubMed, Embase, the China National Knowledge Infrastructure (CNKI), and the Wanfang Database. Inclusion criteria included pre-exposure intervention, year for publication (2007–2021), setting (China), and cost-effectiveness estimation.Results: Seven studies were identified. We found that pre-exposure prophylaxis is only cost-effective among men who have sex with men without prioritization with at least a 5.5% reduction in the market price in the models. Pre-exposure prophylaxis is potentially cost-effective when using the latest market price, combined with other preventive programs or delivered to the population with a high risk of HIV exposure.Conclusion: Our study identifies key considerations in cost-effectiveness evaluation: cost assumptions, implementation coverage, and targeted population. The scarce evidence available is not comparable to some extent. However, combined with the latest market and policy reform, the cost-effectiveness of PrEP could be achieved as estimated by the underlying model of the included studies. Consequently, it calls for more standard and transparent modeling studies that include the latest drug types and market prices.

3 November 2025 in PLOS Global Public Health
Verified
Journal Article
Open access
PDF file
YMYuanqi Mi
Yuanqi Mi
XWXiaofei Wang
Xiaofei Wang
YZYuhong Zeng
Yuhong Zeng
YGYang Guo
Yang Guo
PWPeicheng Wang
Peicheng Wang
MZMengge Zhou
Mengge Zhou
Durability of the initially prescribed antiretroviral therapy (ART) regimen is critical for long-term virologic suppression among people living with human immunodeficiency virus (HIV). However, data on the incidence of regimen modification and its associated factors remain limited in China. We aim to quantify the incidence of initially prescribed ART modification and identify associated baseline factors in China. Treatment-naïve adults (≥18 years) who initiated ART with complete regimen records and have documented follow-up information in Beijing, China, from 2010 to 2020 were included. The primary outcome was initially prescribed ART regimen modification. A multivariable Cox proportional hazards model was applied to evaluate factors associated with modification risk. Of 18,911 participants included, 3,725 (19.7%) participants experienced ART modification over 472,565 person-months of follow-up (PMFU), a rate of 7.9 per 1,000 PMFU. The median follow-up was 32 (IQR 13–36) months. Modification rates peaked in months 0–6: TDF + AZT + NVP and LPV/r + 3TC + AZT exhibited the highest 6-month modification rates (59.4 and 57.7 per 1,000 PMFU, respectively), whereas TDF + 3TC + EFV, the most prescribed regimen, had the lowest early switch rate (8.8 per 1,000 PMFU). In multivariable analysis, baseline white blood cell (WBC) < 4.0 × 10⁹/L and WHO stage II–IV were associated with higher modification risk; missing baseline records of WBC, hepatitis B virus or hepatitis C virus coinfection, and later calendar year of ART initiation were associated with lower modification risk; compared to EFV + 3TC + TDF, LPV/r + 3TC + AZT had the highest modification risk. TDF + 3TC + EFV was the predominant initially prescribed regimen with the highest durability, while LPV/r + 3TC + AZT had the highest modification rate. These findings underscore the need for early ART initiation, comprehensive pretreatment screening, and enhanced early monitoring—especially during the first six months—to optimize regimen selection and minimize unnecessary modification.

10 March 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
YYYicong Ye
Yicong Ye
LLLi Lin
Li Lin
MZMengge Zhou
Mengge Zhou
YDYaodong Ding
Yaodong Ding
YZYang Zhang
Yang Zhang
YZYong Zeng
Yong Zeng
Background: The ISCHEMIA trial demonstrated no overall prognostic benefit of an initial invasive strategy over optimal medical therapy (OMT) in patients with chronic coronary syndrome (CCS) and moderate-to-severe ischemia. However, managing patients with stable angina and low systolic blood pressure (SBP) remains challenging due to limited tolerance to vasodilatory anti-anginal drugs and the uncertain role of revascularization in improving long-term outcomes for this subgroup. Objectives: This study aimed to estimate the treatment effect of an initial invasive strategy (INV) compared with conservative medical therapy (CON) on long-term clinical outcomes and quality of life in patients with stable angina, particularly those with low baseline systolic blood pressure (≤120 mmHg). Methods: We conducted a post hoc analysis of 3544 patients with stable angina from the ISCHEMIA trial, divided into an initial invasive strategy or a conservative approach. The primary endpoint was a 3-year composite of cardiovascular death, myocardial infarction, hospitalization for unstable angina or heart failure, or resuscitated cardiac arrest. Health-related quality of life was assessed using the Seattle Angina Questionnaire (SAQ). In the subgroup, patients were stratified by baseline SBP, diastolic blood pressure (DBP) and heart rate; the Cox model was adjusted for the covariates. Results: Baseline characteristics were generally comparable between the two groups. Over 3 years of follow-up, no significant difference in primary endpoint events was observed between the INV and CON group in the overall cohort (HR = 0.94, 95%CI 0.77–1.14, p = 0.53), and the INV group had the higher SAQ score. Among patients with low baseline SBP (≤120 mmHg), after adjusting for clinical factors using Cox regression, randomized treatment assignment to the INV approach significantly reduced adverse cardiovascular events compared with conservative therapy (HR = 0.58, 95%CI 0.38 to 0.89). Conclusions: In patients with stable angina, an invasive strategy improved long-term quality of life. Among those with low baseline SBP (≤120 mmHg) and limited tolerance to vasodilatory anti-anginal drugs, invasive management reduced 3-year adverse events, supporting tailored revascularization strategies for these patients; a larger cohort is needed for validation. However, this subgroup-specific causal contrast derives from a post hoc exploratory analysis and should be interpreted cautiously; prospective randomized studies are needed to further validate these findings.

2 June 2026 in EP Europace
Verified
Journal Article
Open access
LZLe Zhou
Le Zhou
YZYize Zhao
Yize Zhao
XHXingxing He
Xingxing He
JWJue Wang
Jue Wang
FLFadong Li
Fadong Li
CMChangsheng Ma
Changsheng Ma